• Home
  • Study Details
Open

M24-064: Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF in subjects with Colon Cancer

The purpose of this study is to determine the recommended ABBV-400 dose when ABBV-400 is given alone (monotherapy) in Stage 1, and to assess if ABBV-400 monotherapy is a safe and effective treatment compared to the standard of care (SOC) LONSURF [Trifluridine and Tipiracil] plus Bevacizumab in subjects with c-Met overexpressed (level of c-Met protein in your tumor cells is increased) uncontrolled metastatic colorectal cancer in Stage 2 of the study plan.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Visit Availability

  • Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

If you are eligible to participate in this study, you will undergo one or more of the study procedures at each study visit. Some of these procedures may no longer be necessary depending on the visit day in the study treatment cycle. Your study doctor will let you know if you are not required to undergo a procedure. Please note that you may be asked to repeat a procedure or test and/or have additional procedures if your study doctor feels it is needed to evaluate your condition. Your study doctor may ask you to come in early for some procedures because of scheduling. If not indicated otherwise the listed procedures would be applicable for both stages of the study (Stage 1 and Stage 2) ● Medical/ Cancer/ Surgical history: On Cycle 1 Day 1, any additional medical history observed after signing of the informed consent form but before the first dose of the study drug and not considered related to study-required procedures will be recorded in the medical history. ● Vital Signs (blood pressure, heart rate, respiratory rate, oxygen saturation (SpO2) and body temperature), weight ● You will be asked about: - Any changes to the medications you are taking - Any side effects that you are experiencing, which may or may not be related to the study - If you have made any visits to other doctors or hospitals You will receive an Adverse Event (side effect) and Prior/Concomitant therapy dispensation log and instructions on how to complete it. ● Biomarker and/or exploratory research - Blood/Plasma to help understand the effects or

In-person visits:
12
Total length of participation:
23 months

Looking for Specific Volunteers

Able to participate:

  • Subject has histologically or cytologically confirmed unresectable, metastatic adenocarcinoma of the colon or rectum (all other histological types are excluded)
  • Documented virology status of hepatitis, as confirmed by screening HBV and HCV serology tests.
  • Life expectancy ≥ 12 weeks per investigator assessment.
  • Adequate coagulation function for all patients. For patients receiving anti-coagulant therapy (except platelet anti-aggregates), adequate therapeutic levels should be confirmed.

Not eligible if:

  • History of allergic reactions or hypersensitivity to bevacizumab or any of its excipients, or to compounds similar to trifluridine/tipiracil.
  • History of clinically significant, intercurrent lung-specific illnesses
  • History of other malignancies within 3 years prior to screening, except for malignancies with a negligible risk of metastasis or death
  • Untreated brain or meningeal metastases

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Hanna Sanoff
Medicine- Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Colorectal)

IRB Number

24-2358

ClinicalTrials.gov

NCT06614192

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research